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Abstract
Microsomal triglyceride transfer protein (MTP) was first identified as a major cellular protein capable of transferring
neutral lipids between membrane vesicles. Its role as an essential chaperone for the biosynthesis of apolipoprotein
B (apoB)-containing triglyceride-rich lipoproteins was established after the realization that abetalipoproteinemia
patients carry mutations in the MTTP gene resulting in the loss of its lipid transfer activity. Now it is known that it
also plays a role in the biosynthesis of CD1, glycolipid presenting molecules, as well as in the regulation of
cholesterol ester biosynthesis. In this review, we will provide a historical perspective about the identification,
purification and characterization of MTP, describe methods used to measure its lipid transfer activity, and discuss
tissue expression and function. Finally, we will review the role MTP plays in the assembly of apoB-lipoprotein, the
regulation of cholesterol ester synthesis, biosynthesis of CD1 proteins and propagation of hepatitis C virus. We will
also provide a brief overview about the clinical potentials of MTP inhibition.
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Microsomal triglyceride transfer protein (MTP)
Evidence for an intracellular protein in the lumen of
mammalian liver microsomes that transfers neutral
lipids, triglycerides and cholesterol esters between phos-
pholipid vesicles was first provided by Wetterau and Zil-
versmit [1,2]. The protein exhibits significant preference
for the transfer of neutral lipids (triglycerides and cho-
lesterol esters) compared to phospholipids. Under non-
denaturing polyacrylamide gel electrophoresis condi-
tions, the purified protein migrated as a single band [3].
However, in the presence of 0.1% SDS, two major pro-
tein bands were resolved. The P subunit (~58 kDa) was
identified as the ubiquitous endoplasmic reticulum (ER)
chaperone protein disulfide isomerase (PDI), whereas
the larger M subunit (~97 kDa) was unique [3,4]. There-
fore, MTP is a heterodimer of two distinct subunits.
The role of PDI in MTP activity
PDI is known to facilitate proper disulfide bond forma-
tion during the biosynthesis of nascent proteins. PDI
catalyzes disulfide bond formation via its isomerase and
shufflase activities; both of these activities are lost when
PDI associates with the M subunit. These activities,
however, are recovered after disrupting the heterodimer
with chaotropic agents, such as guanidine HCl, NaClO4
and KSCN, and non-denaturing detergents, octyl b-glu-
coside [4-6]. These data indicate that association of PDI
with the M subunit involves non-covalent, hydrophobic
interactions. This association either physically obstructs
active sites present in PDI or instigates a structural
change disrupting regions responsible for these
activities.
PDI, by itself, lacks lipid transfer activity. Non-cova-
lent association of the M subunit with PDI generates
the fully functional lipid transfer complex, MTP. The
enzymatic activities associated with PDI are unnecessary
when forming an active complex. Missense mutations
introduced via site-directed mutagenesis that disrupt
PDI’s chaperone activities have no effect on heterodi-
merization with the M subunit and on the formation of
a fully functional lipid transfer complex [7]. Disruption
of the MTP heterodimer by various agents results in the
aggregation of the M subunit and loss of lipid transfer
activity [6]. Thus, the role of PDI in the biosynthesis of
MTP is more likely related to structural stabilization
and solubilization of the complex rather than acting as
an active subunit.
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the M subunit is unknown. Attempts to purify the M
subunit and to recombine it with purified PDI have
been unsuccessful [8]. Further, endogenous PDI present
in the complex could not be exchanged in vitro with
excess purified PDI [8]. Thus, it has been postulated
that the M subunit associates with PDI during transla-
tion, although no concrete evidence is available. Once
the MTP complex is formed, the two subunits do not
dissociate from each other. It remains to be determined
whether the complex is degraded en bloc,o rw h e t h e ri t
involves subunit separation followed by selective degra-
dation of the two subunits.
The M subunit
The M subunit belongs to a family of large lipid transfer
proteins (LLTP) [9-11]. These proteins share sequence
homology and have been predicted to contain similar
secondary and tertiary structures. Other members of the
family include apolipoprotein B (apoB), lipophorin, and
vitellogenin. MTP shares extensive sequence homology
with vitellogenin, an ancient protein found in verte-
brates involved in the transport of lipids from extra-
ovarian tissue to the oocyte. By comparison with the
crystal structure of vitellogenin, MTP is predicted to
have three major structural domains: N-terminal b-bar-
rel (amino acid residues 22-297), middle a-helical (AA
residues 298-603), and C-terminal b-sheet (residues
604-894) [12,13]. The N-terminal b-barrel domain med-
iates interaction with the N-terminus of apoB; the mid-
dle a-helical domain associates with both PDI and
apoB; and the C-terminal b-sheet domain contains both
the lipid binding and lipid transfer activity of MTP
[12,14].
The importance of the M subunit of MTP in apoB-
lipoprotein assembly was first realized by the observa-
tion that individuals with abetalipoproteinemia lack
apoB-lipoproteins in their plasma and have mutations in
the MTTP gene that result in the loss of lipid transfer
activity present in the liver and intestine [15]. Abetalipo-
proteinemia is a rare autosomal recessive disease [15-17]
characterized by a virtual absence of plasma apoB-con-
taining lipoproteins [18]. Due to fat malabsorption and
defective lipid transport, intestinal biopsies from abetali-
poproteinemia patients grossly demonstrate a whitish
coating and histologically visible fat-laden enterocytes.
Additionally, these patients have decreased plasma tri-
glyceride and cholesterol levels, altered membrane and
lipoprotein lipid compositions, and fat soluble vitamin
deficiencies (D, A, K, and E) [19]. The clinical manifes-
tations of abetalipoproteinemia, first described by Bassen
and Kornzweig, range from gastrointestinal (steatorrhea,
diarrhea, failure to thrive), neurological (absent reflexes,
altered sensation and movement, muscle weakness),
hematological (acanthocytes, anemia, coagulopathy) to
ophthalmological (pigmentary degeneration of the retina
and night blindness) symptoms [19].
Lipid transfer activities of MTP
The lipid transfer activities of MTP are measured in
vitro using donor and acceptor vesicles [1,3]. Donor
vesicles consist of unilamellar (one bilayer) phosphati-
dylcholine with trace amounts of radiolabeled lipids, i.e.
triglycerides or cholesterol esters, and cardiolipin. After
incubating donor and acceptor vesicles with a source of
MTP, DEAE-cellulose (DE52) is added to remove cardi-
olipin containing vesicles. Acceptor vesicles in the
supernatant are then counted and loss of radioactivity is
used to calculate % lipid transfer per h.
Wetterau and associates also engineered donor vesi-
cles containing fluorescent cholesteryl ester, cholesteryl
1-pyrenedecanoate, and incubated with acceptor vesicles
to quantify MTP activity [6]. Following excitation at 340
nm, pyrene exhibits a complex emission spectra consist-
ing of two peaks. The first emission is observed at 380
nm (monomer emission) and the second is observed at
470 nm (excimer or excited-state dimer emission). Time
dependent reduction in excimer/monomer fluorescence
ratio was correlated with the lipid transfer activity of
MTP. The transformation of the excimer/monomer
ratio to lipid transfer activity is not linear and conse-
quently is neither suitable for routine MTP activity mea-
surements nor for comparison of activity in samples of
different origins. Subsequently, they reported that the
monomer emission of cholesteryl 1-pyrenedecanoate at
380 nm was self-quenched when incorporated at higher
concentrations into phosphatidylcholine vesicles [20]
and observed that incubation of these vesicles with
MTP increased fluorescence due to the binding of cho-
lesteryl 1-pyrenedecanoate to MTP [20]. These studies
were further extended to demonstrate that pyrene-
labeled phospholipids and triglycerides also bind to
MTP [21]. The disadvantages of the use of pyrene
include the need to measure emission spectra at two dif-
ferent wavelengths and variability in emission spectra
under different conditions and concentrations.
We described a different MTP assay that measures the
transfer of nitrobenzoaxadiazol (NBD)-labeled triacylgly-
cerols between vesicles [22]. In this assay, fluorescent
lipids are quenched within the phospholipid bilayer of
donor vesicles. Incubation of donor vesicles with the
acceptor vesicles in the presence of different concentra-
tions of MTP results in an increase in fluorescence with
time. Once the fluorescent lipids are transferred to
acceptor vesicles the fluorescence is once again
quenched. This actual transfer to the acceptor vesicles
can be measured after their separation by incorporating
cardiolipin and dissolution with isopropanol [23]. Thus,
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fluorescent lipids being transferred by MTP between
donor and acceptor vesicles, and the saturation of lipid
transfer represents the maximum occupancy of MTP
with fluorescent lipids. This assay has been further
refined to determine the transfer of cholesterol esters
and phospholipids [23]. For phospholipid transfer activ-
ity, NBD-labeled phosphatidylcholine was a poor sub-
strate as it could not be easily quenched within vesicle
membranes. However, NBD-labeled phosphatidylethano-
lamine incorporated in phosphatidylethanolamine vesi-
cles could be used as donor vesicles to monitor the
phospholipid transfer activity of MTP. These assays are
simple and amenable to throughput screening.
MTP expression in different tissues
The M subunit expression and MTP activity is predomi-
nantly present in differentiated epithelial cells of the
small intestine. MTP expression varies both longitudin-
ally throughout the intestine and vertically within the
crypt-villus axis [24-26]. Maximal expression occurs
starting from the pyloric to intestinal transition in the
duodenum, proximal jejunum, decreases towards the
distal end and in the ileum, and is nearly absent in the
colon [24]. Isolated crypts contain non-differentiated
enterocytes and are devoid of both MTP mRNA and
protein [26]. A graded increase in mRNA and protein
levels occurs as enterocytes mature from the crypts
toward the villi.
The liver is another major site of MTP expression in
mammals. To date, only hepatocytes have been shown
to express MTP. Within the liver, it has been reported
that protein expression increases in cells proximal to the
central vein and lessens toward the periphery of the
lobule opposing the portal triad [27]. The physiological
basis for this distribution demands further investigation.
The major function of MTP in hepatocytes, as well as
the previously discussed enterocytes, is to mobilize diet-
ary and endogenous fat to other tissues through its
incorporation into apoB-lipoprotein particles.
Since first described as a liver and intestine specific
protein, our appreciation of MTP’s tissue distribution
has further evolved. Recent studies show that kidney
and heart are the 3
rd and 4
th major organs expressing
MTP [28]. Nevertheless, the amounts of MTP mRNA in
these tissues are 3-5% of the liver levels. In the kidney,
MTP is expressed in the tubular epithelial cells of the
cortex but not in glomerular cells [28]. These cells also
express apoB and secrete lipoproteins. It has been
speculated that cortical cells might synthesize lipopro-
teins to recycle albumin bound fatty acids and vitamin
A from the glomerular filtrate. MTP expressed in car-
diac myocytes also functions in the assembly and secre-
tion of apoB-lipoproteins [29-32]. The key purpose for
lipoprotein assembly in the heart appears to be to pro-
tect this organ against the toxic accumulation of lipids.
In animal models of hypoxia and diabetes, MTP activity
is reduced and more lipids accumulate in the heart
[32-34].
MTP is also expressed in the retina [35]. MTP protein
was detected in retinal tissue as well as in a sponta-
neously arising transformed cell line that was shown to
support secretion of apoB lipoproteins. A role similar to
that illustrated for the myocardium may also be ascribed
to MTP in the retina. Like heart, the retina is suscepti-
ble to lipid accumulation with the formation, as well as
deposition, of cholesterol crystals. The localized deposi-
tion is associated with age-related maculopathy [35].
Further, MTP has also been reported to be expressed in
neurons [35]. While speculative, it is likely to play a
similar protective role that has been described in heart
and retina.
It has long been recognized that MTP is expressed in
the yolk sac of certain mammals [36] and is reported to
be present in human placenta [37]. Cultured adipocytes,
as well as fat tissue extracts from the heart and adrenal
glands, also contain MTP [38,39]. Recent studies have
shown that immune cells, especially lipid antigen pre-
senting cells, contain both MTP transcripts as well as
functional protein capable of transferring lipids [40,41].
Thus, MTP is more widely expressed than anticipated
during early studies. MTP expression is high in cells
that synthesize lipoproteins, but low in other cells. Low
levels of MTP might be sufficient for the biosynthesis of
CD1 proteins (see below). Higher amounts of MTP are
perhaps needed for the assembly and secretion of apoB-
containing lipoproteins. Tissue-specific cis-a n dtrans-
elements responsible for variable MTP expression have
yet to be defined.
Recent studies point to the expression of two isoforms
of MTP, only in mice, that arise from differential spli-
cing of alternate exon 1 [39,42]. Despite two extra N
terminal amino acids in the minor MTP-B isoform, both
isoforms have similar lipid transfer properties. The
major difference is related to their expression. The
expression of the major MTP-A isoform is predominant
in the liver, intestine and heart, whereas MTP-B isoform
is mainly operative in macrophages and other cells that
express low levels of MTP.
Functional consequences of tissue specific ablation of
MTP
Two groups have shown that MTP knockout in mice is
lethal [43,44]. MTP deficiency leads to embryonic lethal-
ity predominantly between E9.5 and E10.5 [43]. Yolk
sacs of MTP
-/- embryos contained significant amounts
of lipid droplets, but lacked VLDL-size lipoproteins in
their ER and Golgi compartment. Thus, a reason for
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the yolk sac to synthesize lipoproteins for the delivery of
lipids to embryos.
MTP
+/- mice on chow diet have half of normal
mRNA, protein and activity levels. These mice have
similar plasma cholesterol and triglyceride levels as
MTP
+/+ mice, but they have lower levels (reductions of
~28%) of plasma apoB100 [43]. The livers of MTP
+/-
mice contained higher (~20%) cholesterol and triglycer-
ide levels and showed signs of increased lipid accumula-
tion by Oil Red-O staining. On a high fat diet, MTP
+/-
mice had ~20% lower levels of plasma cholesterol
mainly due to reductions in VLDL/LDL. ApoB produc-
tion studies showed significant reductions (~20%) in the
secretion of newly synthesized apoB100 and apoB48 by
isolated primary hepatocytes from MTP
+/- mice. Thus,
both MTP alleles are required for normal plasma and
hepatic lipid levels.
Chang et al. [44] and Raabe et al. [45] have floxed
exons 5/6 (MTTP
fl(exon5, 6)/fl(exon5, 6))a n de x o n1
(MTTP
fl(exon1)/fl(exon1)), respectively, of the MTP gene in
mice to facilitate tissue-specific ablation. Chang et al.
[44] generated liver specific MTP ablated (L-MTP
-/-)
mice by injecting adenoviruses expressing Cre-recombi-
nase. Hepatic MTP ablation reduced plasma apoB100
and apoB48 mainly due to lower production of apoB-
lipoproteins. Moreover, L-MTP
-/- were resistant to high-
cholesterol diet induced hypercholesterolemia. Thus,
hepatic MTP expression has a significant effect on
plasma cholesterol levels.
Raabe et al. [45] crossed MTTP
fl(exon1)/fl(exon1) mice
with mice expressing Cre-recombinase under the con-
trol of Mx1 promoter. The Mx1 promoter is activated
after the injection of dsRNA leading to the synthesis of
Cre-recombinase and deletion of MTP gene. Addition-
ally, they deleted hepatic MTP by injecting adenoviruses
expressing Cre-recombinase. Using both these
approaches they achieved > 95% hepatic MTP defi-
ciency. L-MTP
-/- mice had ~50% less plasma cholesterol
and 30-40% less plasma triglyceride compared with
floxed mice. They reported > 95% reductions in plasma
apoB100 but a modest ~20% reductions in plasma
apoB48. L-MTP
-/- hepatocytes had several lipid droplets
and reduced glycogen levels. These hepatocytes did not
show signs of inflammation. Electron microscopic obser-
vations showed cytosolic lipid droplets, absence of
VLDL-size particles in the ER and Golgi. L-MTP
-/- mice
were found to be more susceptible to E. coli lipopolysac-
charide, concavalin A and P. aeruginosa exotoxin A
induced injury [46].
Khatun et al. crossed MTTP
fl(exon1)/fl(exon1) mice with
Albumin-Cre mice to obtain liver specific ablation of
MTP [47]. MTTP gene deletion in these L-MTP
-/- mice
reduced triglyceride transfer activity by ~80-85%. Livers
of these mice had higher levels of triglyceride, choles-
terol and phospholipids. Further, these mice had signifi-
cantly lower levels of plasma lipids. Lipoprotein
synthesis studies revealed that hepatic MTP ablation sig-
nificantly reduces assembly and secretion of both
apoB100 and apoB48 lipoproteins. These three L-MTP
-/-
studies clearly establish the essential role of hepatic
MTP in the production of VLDL and maintenance of
plasma cholesterol and hepatic lipids.
Davidson and associates created intestine specific KO
mice (I-MTP
-/-) after crossing MTTP
fl(exon1)/fl(exon1) mice
with mice that express Cre-recombinase under an indu-
cible Villin promoter activated by tamoxifen [48,49].
Intestinal MTP gene deletion was associated with no
weight gain and steatorrhea, gross lipid accumulation,
presence of large lipid droplets in the apical portions of
the enterocytes and absence of lipoproteins in the Golgi
and ER [48]. MTP deficient enterocytes contained about
12-fold and 2-fold increase in triglyceride and free fatty
acids, respectively [48]. Plasma lipid analysis revealed
significant reductions in plasma triglyceride, cholesterol
and free fatty acids due to reductions in both apoB-lipo-
proteins and HDL. These intestine-specific MTP defi-
cient mice showed almost no absorption of triglycerides
and 60-70% reduction in cholesterol absorption. Further,
radiolabeling studies with isolated enterocytes revealed
that MTP deficiency was associated with significant
reductions in apoB48 secretion. These studies establish
that MTP activity is essential for the assembly and
secretion of apoB48-containing lipoproteins by entero-
cytes and that intestinal MTP contributes significantly
to steady state plasma lipids.
Xie et al. [49] further examined the role of intestinal
MTP in the assembly and secretion of apoB48 and
apoB100 containing lipoproteins. Enterocytes only
synthesized apoB48 due to efficient and complete post-
transcriptional editing of the apoB mRNA by Apobec-1
enzyme [50,51]. Ablation of Apobec-1 results in the
synthesis of apoB100 by the intestine [50,52]; therefore,
they crossed Apobec-1
-/- mice with intestine-specific
MTP deficient mice to obtain apoB100 expressing intes-
tine specific MTP deficient mice (apoB100-I-Mttp
-/-)
and studied the effect of MTP deficiency on the secre-
tion of apoB100-lipoproteins. They observed that
apoB100-I-Mttp
-/- mice were more susceptible to death
than apoB48-I-Mttp
-/- mice when fed high saturated or
unsaturated fat but not when fed a high cholesterol diet.
Investigators made two novel observations that could
explain increased lethality in apoB100-I-Mttp
-/- mice.
First, they observed that apoB100-I-Mttp
-/- mice did not
adapt to high fat feeding by increasing the length of the
small intestine as apoB48-I-Mttp
-/- mice did mainly due
to a defect in crypt proliferation. Second, apoB100-I-
Mttp
-/- enterocytes developed unresolved ER stress
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the ER stress can perhaps be attributed to accumulation
of apoB100 in the ER. It is known that unresolved ER
stress could lead to cell death [53]. Thus, induction of
unresolved ER stress might have contributed to cell
death and no increase in villus length.
Iqbal et al. [54] obtain partial MTP gene deletion in
the intestine by crossing MTTP
fl(exon5, 6)/fl(exon5, 6) mice
with Villin-Cre mice. These mice had ~60-70% lower
levels of intestinal MTP mRNA and activity compared
with floxed mice. [
3H]Triolein absorption studies
revealed that these mice absorb ~63% less triglyceride in
2 h. These studies showed that partial ablation of MTP
gene also has significant effect on acute lipid absorption.
Bjorkegren et al. [55] crossed MTTP
fl(exon1)/fl(exon1)
mice with a-myosin heavy chain-Cre transgenic mice to
generate cardiac myocytes specific ablation of the MTP
gene. Heart specific MTP ablation (H-MTP
-/-) increased
triglycerides in cardiac myocytes in fasting mice. They
did not report changes in MTP activity in these mice.
Further, they showed that MTP inhibitors reduce secre-
tion of apoB-containing triglyceride-rich lipoproteins by
these cells. On the other hand, Bartels et al. [56] crossed
MTTP
fl(exon1)/fl(exon1) mice expressing Cre-recombinase
u n d e rt h ec o n t r o lo fm u s c l ec r e a t i n ek i n a s ep r o m o t e r
that is specific for skeletal and cardiac muscle cells. Sur-
prisingly, they did not find any difference in MTP activ-
ity because the expression of MTP-A isoform was
reduced by > 95% with a concomitant ~3.6-fold increase
in the expression of MTP-B isoform. Both these studies,
in combination with those involving altering apoB
expression in the heart [29-31,55,57], support the notion
that lipoprotein assembly by the heart might be to avoid
cardiac lipotoxicity associated with influx of free acids
during fasting or high fat feeding.
MTP as the precursor to extracellular lipid
transport systems
Lipoprotein-based lipid transport systems are also pre-
sent in the plasma of egg laying animals and the hemo-
lymph of insects. Unlike mammals, the lipid transport
vehicles utilized by these organisms are not apoB-based,
but instead rely on proteins with similar structure and
varying capacities to carry lipids.
Insects synthesize a single multifunctional lipoprotein,
lipophorin, within a specialized organ identified as the
fat body [58]. Lipophorin typically consists of two apoli-
poproteins, apolipophorin I and apolipophorin II (~ 240
and 80 kDa, respectively). A third, apolipophorin III
(18-20 kDa), may also be present to increase the overall
lipid carrying capacity of the lipoprotein [59]. Lipo-
phorin is a phospholipid rich, neutral lipid poor lipopro-
tein whose density is similar to mammalian HDL (~
1.15 g/ml). The principal neutral lipid varies between
triglyceride and diglyceride depending on the organism,
while cholesterol ester is present in very low amounts
[60]. Apolipophorin has the capacity to accept lipids via
efflux from tissue (i.e. intestine) and can then deliver
these to another, distant tissue without undergoing
endocytosis. It therefore behaves as a continuous “lipid
shuttle” that never leaves the circulation. However,
some evidence does suggest that in Locust migratoria
apolipophorin may be endocytosed similar to certain
mammalian lipoproteins through an insect homolog to
the mammalian low-density lipoprotein receptor [61].
Egg laying animals utilize a different lipoprotein, vitel-
logenin. This large apolipoprotein (~ 450 kDa) is
synthesized in the liver of vertebrates and the intestines
of nematodes. The major function of vitellogenin is to
transport lipids to the ovary/oocytes. There it undergoes
receptor-mediated endocytosis via a member of the low
density-lipoprotein receptor family [62,63]. Vitellogenins,
like lipophorins, are phospholipid rich, dense lipopro-
teins containing ~15% lipid by mass. Vitellogenins
described to date contain the bulk of neutral lipids as
triacylglycerols and not diacylglycerols.
Apolipophorin, vitellogenin and apoB are functionally
related in that each constitutes a vehicle for extracellular
lipid transport. Surprisingly, their overall relationship
extends to amino acid sequence, conservation of critical
cysteine residues identified to be involved in disulfide
bond formation, residues required for the development
of salt-bridges, as well as an overall maintenance of sec-
ondary structure (a-helical and b-sheet). These homolo-
g i e sp r o v i d ee v i d e n c et h a ta p o lipophorin, vitellogenin,
and apoB are distant relatives who have undergone
paralogous development [13]. As a group, they comprise
the Large Lipid Transfer Protein Gene Family (LLTP)
[64]. Microsomal triglyceride transfer protein is also pre-
dicted to be a member of the LLTP family based upon
sequence homology [13]. Unlike other family members,
MTP does not directly participate as a vehicle for trans-
porting lipid to distant tissues. It is restricted to the
intracellular compartments of the secretory pathway and
is critical for the assembly of apoB and vitellogenin con-
taining lipoproteins. It has been suggested that MTP
could be the ancient protein evolved to transfer lipids
[9]. The other members may have diverged to carry
lipids as a cargo rather than to act as an intracellular
shuttle protein for lipid transfer.
Human MTP homologues have been reported
throughout a diverse collection of organisms that
include mammals [65], birds [66], fish [67], insects [68],
and worms [69]. While our appreciation regarding the
role of MTP in mammalian apoB lipoprotein assembly
and secretion is expansive, its function in organisms
that do not express apoB has only recently been studied.
As described for human MTP, these more ancient forms
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[70,71]. Not only does this confirm the presence of
MTP in distinct non-mammalian organisms, but this
also suggests its mechanism for retention within the ER
is preserved as well.
As has been appreciated for apoB lipoprotein assem-
bly, recent evidence suggests that MTP may also be
required for the secretion of vitellogenin [9]. When
expressed by itself, vitellogenin is not secreted from a
monkey kidney epithelial COS cells. However, co-
expression with human MTP rescues its secretion simi-
lar to that of apoB. Further, expression of an insect
(Drosophila) MTP ortholog in a heterologous system
supported secretion of human apoB as a high-density,
lipid-poor particle [68,70] and in mice as triglyceride-
poor VLDL as well as phospholipid-rich HDL [47]. Sur-
prisingly the Drosophila ortholog lacked triglyceride
transfer activity. Later studies showed that the Droso-
phila MTP is as efficient as the human MTP in transfer-
ring phospholipids [70,71]. Thus, it appears that
phospholipid transfer activity may be the ancient lipid
transfer activity present in the earliest orthologs of
MTP. The neutral lipid transfer activity, predominant in
human MTP, might have been acquired later, during a
transition from invertebrates to vertebrates [71], as the
lipid rich carrier apoB evolved.
Role of MTP in apoB-lipoprotein assembly
Nature has devised different methods to transport
hydrophobic lipids in the aqueous environment of the
body and tissue fluids. In the intestinal lumen, bile acid
micelles solubilize dietary lipids, as well as other hydro-
phobic molecules, thereby facilitating their transport to
enterocyte membranes for cellular uptake. Intracellu-
larly, various proteins transport lipids to, and within,
specific subcellular compartments. In the extracellular
milieu, lipids are escorted between tissues by unique
lipid-protein emulsions known as lipoproteins that pos-
sess an amphiphatic surface surrounding a hydrophobic
core of neutral lipids, i.e. triacylglycerols and cholesterol
esters. The surface layer contains a combination of
phospholipids, free cholesterol, and amphiphilic pro-
teins. In mammals, lipoproteins are synthesized predo-
minantly in the intestine and liver. Of the various
classes, apoB-lipoproteins have been of great interest
owing to their enormous capacity to transport large
amounts of triglycerides and their association with
atherosclerosis and coronary artery disease.
The MTP’s role in the assembly of apoB lipoproteins
has been extensively studied and reviewed elsewhere
[12,14,51,72,73]. MTP’s requirement during apoB lipo-
protein assembly was first demonstrated by linking abe-
talipoproteinemia with mutations in the M subunit
[15,17]. Three independent functions, apoB-binding,
membrane association, and lipid transfer, of MTP have
been appreciated [12,14]. MTP was demonstrated to
interact with apoB by co-immunoprecipitation, yeast
two-hybrid analysis, and solid phase in vitro binding
assays [for review, [12,14]]. These contacts were shown
to be mediated through a region within the N-terminus
of apoB [13,74]. Inhibition of protein-protein interac-
tions by small molecule inhibitors decreased apoB secre-
tion in cell culture models [75]. This suggested that not
only did MTP and apoB interact within the secretory
pathway, but that this interaction was necessary for the
secretion of apoB lipoproteins. The lipid transfer activity
associated with MTP is also vital for lipoprotein assem-
bly and secretion. Naturally occurring missense muta-
tions in the M subunit that result in loss of lipid
transfer activity [76,77] as well as pharmacological inhi-
bition of MTP lipid transfer activity decrease the
a m o u n t so fa p o Bs e c r e t e d[ 7 8 ] .T h u s ,b o t ht h el i p i d
transfer and apoB-binding properties of MTP are
involved in apoB-lipoprotein assembly.
Although MTP is classically identified for its ability to
transfer neutral lipids, it also transfers phospholipids.
Identification of a Drosophila ortholog of MTP that
transfers phospholipids, but not triglycerides
[47,68,70,71], provided additional novel insights about
the need of different lipid transfer activities in apoB-
lipoprotein assembly and secretion. First, Drosophila
MTP was shown to rescue apoB secretion despite lack-
ing triglyceride transfer activity [68]. Subsequently, we
showed that in addition to rescuing apoB secretion, Dro-
sophila MTP also responds to oleic acid supplementa-
tion and increases apoB secretion in cells [70].
Nonetheless, the Drosophila MTP was found to be
~50% as efficient as the human MTP in promoting
apoB-lipoprotein assembly and secretion. These studies
have now been extended to mice. Khatun et al. [47]
have shown that Drosophila MTP can assemble apoB-
lipoproteins in mouse livers. They found that Drosophila
MTP assists in the assembly of triglyceride-poor
apoB100- and apoB48-VLDL and phospholipid rich
apoB48-containing HDL size particles. Hence, the phos-
pholipid transfer activity of MTP is sufficient for the
assembly and secretion of primordial lipoprotein parti-
cles. The presence of triglyceride transfer activity along
with the phospholipid transfer activity, as in the human
MTP, increases the number of particles assembled as
well as the amounts of neutral lipids associated with
them.
Though the major forms of apoB used in vivo for lipo-
protein assembly are apoB48 and apoB100, C-terminally
truncated forms of apoB have been used to decipher
initial steps involved in the molecular assembly of apoB-
containing lipoproteins and the role of MTP in their
lipidation. The N-terminal ba1 domain (amino acids 1-
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deletion does not result in lipoprotein formation [79,80].
This N-terminal fragment has several important func-
tional and biochemical properties. First, several disulfide
bonds are present that are critical for lipoprotein assem-
b l y[ 8 1 , 8 2 ] .F u r t h e r ,t h i ss e g m e n ti n t e r a c t sw i t hM T P
through ionic interactions [83,84].
Secretion studies using various C-terminally truncated
f o r m so fa p o Br e v e a l e dt h a tN - t e r m i n a lf r a g m e n t so f
apoB, up to apoB25 (1134 amino acids), are secreted
independent of MTP [85,86]. Analyses of secreted apoB
peptides showed that these peptides are associated with
lipids [85-90]. Further studies have suggested that a
region between B17 (771 amino acids) and B25 can
associate with lipids. Based on these observations, it has
been proposed that these N-terminal fragments of apoB
associate with lipids in the inner leaflet of the ER and
initiate the formation of “nucleation sites” on the ER
membrane. Thus, initial interaction of apoB with lipids
might take place independent of MTP. In the absence of
the synthesis of larger hydrophobic sequences of apoB,
the assembly of lipoproteins is aborted, and these pep-
tides are secreted from cells associated with these lipids.
However, when larger more hydrophobic peptides such
as apoB48 and apoB100 are translated, MTP assists in
bringing phospholipids and triglycerides to these pep-
tides. In the absence of MTP these peptides are
degraded by proteasomes [91,92]. Our studies indicate
that the phospholipidation of these larger peptides can
be accomplished by Drosophila MTP [47]. In the pre-
sence of additional triglyceride transfer activity, as is
inherent to human MTP, lipidation and assembly of
lipoproteins becomes more efficient and neutral lipid
rich, buoyant lipoproteins are generated. Therefore,
MTP renders naturally occurring larger apoB-peptide
secretion competent by assisting their lipidation. The
degree of lipidation depends on the length of the apoB-
peptide, amount and type of endogenous lipids, and the
inherent lipid transfer activities of MTP.
Earlier studies using MTP inhibitors indicated that
secretion of apoB100 is more sensitive than apoB48
secretion [90]. Similar lesser dependence on MTP for
apoB48 secretion was reported after hepatic ablation of
MTP [45]. Studies of Xie et al. showed that secretion of
apoB48 by enterocytes is dependent on MTP activity as
intestine-specific deletion of MTP by 80% dramatically
reduces apoB48 secretion by enterocytes, significantly
reduces plasma lipids, and causes lipid accumulation in
the intestine [48]. Secretion of both apoB100 and
apoB48 from non-hepatic, non-intestinal cell lines
requires MTP. Further, abetalipoproteinemia patients
exhibit deficiency of both apoB48 and apoB100. Thus, it
is clear that secretion of both the polypeptides require
MTP. However, lesser amounts/activity of MTP might
be sufficient for apoB48 lipidation/secretion, and there-
fore its secretion is less susceptible to MTP inhibition.
Cholesterol ester biosynthesis
A physiological ratio of free cholesterol/phospholipids in
the cellular membrane is necessary to maintain mem-
brane fluidity and excess cellular free cholesterol is toxic
to cells [93]. Hence, cellular free cholesterol levels are
controlled by several pathways. One mechanism is to
convert excess cellular free cholesterol and store it in
ester forms. Two acyl-CoA:Cholesterol acyltransferase
(ACAT) enzymes, ACAT1 and ACAT2, carry out simi-
lar cellular cholesterol esterification, but have different
tissue distributions [for reviews, [94-98]]. ACAT1 is pre-
sent in a variety of tissues [99-102], whereas ACAT2 is
mainly expressed in enterocytes and hepatocytes
[99,102-104]. Both ACAT1 and ACAT2 are integral
membrane proteins with multiple transmembrane
domains [105-107] and reside in the ER. They attach
fatty acids from fatty acyl-CoA to the 3-hydroxyl group
of membrane-associated cholesterol. Newly synthesized
cholesteryl esters are first partitioned into the ER mem-
brane, where these enzymes reside, and are later trans-
ported for storage or secretion. In the liver and
intestine, cholesteryl esters are transferred to apoB-lipo-
proteins that are being synthesized by MTP for secre-
tion. Therefore, inhibition/deficiency of MTP is
expected to increase cellular cholesteryl esters. In con-
trast, Iqbal et al reported that Mttp gene deletion
increases free cholesterol [108]. They showed that MTP
inhibition or genetic ablation had no effect on ACAT1
and ACAT2 mRNA and protein levels [108]. Microso-
mal cholesteryl ester biosynthesis was, however, severely
curtailed when MTP activity was reduced. Thus, MTP
modulates cholesteryl ester synthesis by mechanisms
other than transcriptional or translational control of
enzymes critical for cholesterol ester biosynthesis.
To understand why MTP inhibition/deficiency leads to
free cholesterol accumulation, they studied cholesterol
ester biosynthesis in vitro using hepatic microsomes iso-
l a t e df r o mM T Pd e f i c i e n tm i c ea n do b s e r v e ds i g n i f i c a n t
reductions. Interestingly, supplementation of these
microsomes with purified MTP restored cholesterol
ester biosynthesis without affecting triglyceride and
phospholipid biosynthesis. They also studied acute
effects of MTP and ACAT inhibition using specific inhi-
bitors in intestinal and hepatic cells. Individually, both
inhibitors reduced cellular cholesterol esterification to
similar extents and in combination they exhibited an
additive effect. These studies indicated that MTP and
ACAT affect different pathways in cholesterol ester
biosynthesis.
To identify two different steps necessary for optimal
cholesterol esterification, MTP and ACAT were
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Expression of ACAT increased cholesterol esterification;
however, expression of MTP reduced cholesterol ester
synthesis. Further studies showed that increased synth-
esis of cholesterol esters also requires apoB; expression
of MTP and apoB48 in ACAT expressing cells increased
cholesterol ester synthesis and secretion. Therefore, cho-
lesterol ester synthesis and lipoprotein biogenesis act in
concert to maximize cholesterol ester biosynthesis. To
delineate further how these pathways coordinate in opti-
mal cholesterol ester synthesis and to identify molecular
steps involved in this process, they reconstituted choles-
terol ester synthesis in vitro using liver microsomes,
purified MTP, and LDL. Enrichment of microsomes
with cholesterol esters reduced cholesterol ester bio-
synthesis indicating that product accumulation inhibits
this process. This inhibition was avoided when purified
MTP and LDL was included in the reaction mixture.
These studies suggest that MTP circumvents product
inhibition by removing cholesterol esters and depositing
them into apoB-lipoproteins.
Based on these studies, the role of MTP in cholesterol
ester biosynthesis and consequences of MTP and/or
ACAT deficiency on cellular cholesterol homeostasis
can be explained as follows. Under normal conditions,
ACAT synthesizes cholesteryl esters and MTP transfers
both free and esterified cholesterol to apoB-lipoproteins
(Figure 1A). When MTP is limiting, transfer of both
free cholesterol and esterified cholesterol to apoB-lipo-
proteins is curtailed leading to accumulation of both
esterified and free cholesterol. Accumulation of esteri-
fied cholesterol inhibits esterification by ACAT enzymes
contributing to further accumulation of free cholesterol
(Figure 1B). Why doesn’t free cholesterol accumulate in
the absence of ACAT? We speculate that in lipoprotein
producing cells free cholesterol in the ER membrane is
removed by the MTP thereby avoiding its accumulation
(Figure 1C).
Biosynthesis of cluster of differentiation 1 (CD1)
proteins
The main function of CD1 proteins is to present micro-
bial, viral and parasite lipids to restricted populations of
T lymphocytes that affect both the innate and adaptive
immune response. These proteins present both endo-
genous and foreign lipids, glycolipids and lipopeptides,
to iNKT and CD1-restricted T cells and elicit cytokine
release [109-115]. These non-polymorphic molecules
have been divided into 3 groups based on sequence
homology. Group 1 consists of CD1a, CD1b and CD1c
whereas Groups 2 and 3 contain CD1d and CD1e,
respectively [109]. Humans express all three groups, but
rodents only express group 2 CD1d proteins. Group 1
proteins are mainly expressed by professional antigen-
presenting cells as well as thymocytes and present lipid
antigens to clonally diverse T cells. In contrast, group 2
CD1d is broadly expressed in various tissues including
hepatocytes and enterocytes [111] and present lipid anti-
gens to a specialized group of T cells known as iNKT
cells. CD1e has not been observed on the cell surface
and, therefore, whether or not it plays a similar role in
antigen presentation remains unknown [109].
CD1 molecules are transmembrane, major histocom-
patibility complex like glycoproteins that form heterodi-
mers with b2-microglobulin [109,110]. They have 3
major extracellular a-helical domains. The a1a n da2
domains constitute a deep, hydrophobic, lipid binding
groove while the a3-domain interacts non-covalently
with b2-microglobulin [109,110,115,116]. The lipid moi-
ety of the glycolipid and lipopeptide antigens is
embedded into the hydrophobic groove, whereas the
carbohydrate and peptide moieties are exposed permit-
ting interaction with cell surface receptors present on T
cells. Hence, the specificity of CD1/T cell recognition
depends on cell surface CD1 molecules, their associated
lipid antigens, and the repertoire of different T cell
receptors.
CD1 molecules are synthesized with a signal sequence
that directs them to the ER (Figure 2) where these pro-
teins undergo post-translational modifications that
include glycosylations, heterodimerization with b2-
microglobulin and association with lipids [117]. Associa-
tion with b2-microglobulin and lipids is critical for the
cell surface expression of newly synthesized group 1
CD1 molecules, but not for group 2 CD1d. CD1d mole-
cules can reach the cell surface independent of their
association with either b2-microglobulin or lipids
[109,110,118]. Once on the cell surface, CD1 molecules
are internalized and transported to endosomes and lyso-
somes where endogenous lipids are exchanged with for-
eign lipid antigens with the help of saposins; these
proteins remove endogenous lipids from CD1 molecules
and then deposit a foreign lipid onto the CD1 proteins
[119,120]. While the loading of foreign lipids is to sti-
mulate an immune response, the initial association with
endogenous lipids may be required for structural integ-
rity and transport in addition to desensitizing the
immune system to self-lipid antigens.
Several studies have shown that MTP plays a critical
role in the loading of endogenous lipids onto newly
synthesized CD1 molecules in the ER (Figure 2). Brozo-
vic et al. [40] showed that MTP co-precipitates with
CD1d from mouse hepatocytes and deletion of the Mttp
gene increases peri-nuclear retention of CD1d while
reducing their cell surface expression. A functional con-
sequence of reduced CD1 expression is that these MTP
deficient hepatocytes are less efficient in eliciting secre-
tion of IL-2 by NKT cells in the presence of a-
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bic domain on the CD1d surface. Intestinal cells also
respond to a- galactosylceramide and induce secretion
of IL-2 by NKT cells and MTP knockdown reduces this
response. Further, oxazolone-induced colitis and asso-
ciated weight loss is suppressed in MTP-deficient mice.
These studies suggested that MTP transiently associates
with CD1d and regulates CD1d-mediated antigen pre-
sentation in hepatic and intestinal cells.
Subsequently, evidence that MTP plays a role during
CD1d antigen presentation in various antigen presenting
cells was provided by Dougan et al. [41]. They showed
that MTP is expressed in various antigen presenting
cells, such as monocytes, B cells, splenocytes, bone mar-
row and monocyte derived dendritic cells and that lipid
transfer activity can be measured in lysates obtained
from these cells. Inhibition of MTP activity using
chemical inhibitors reduced the ability of splenocytes
and dendritic cells to present both endogenous and for-
eign antigens to NKT cells. Further, MTP knockdown in
human monocyte cell line U937 also reduced antigen
presentation by CD1d to NKT cells. Moreover, human
B cell line C1Rd was sensitive to MTP inhibition and
was reticent in presenting a- galactosylceramide to NKT
cells. Thus, MTP also plays a role in antigen presenta-
tion by CD1d in a variety of antigen presenting cells.
Sagiv et al. [121] studied intracellular trafficking of
newly synthesized CD1d and showed that MTP defi-
ciency does not affect the rates of CD1d biosynthesis,
glycosylation, maturation and internalization from the
cell surface. However, MTP deficiency profoundly atte-
nuated loading of antigen and recycling from lysosomes
to the plasma membrane. Since MTP has not yet been
shown to be present in lysosomal compartments, a likely
Figure 1 Role of MTP in cellular cholesterol ester biosynthesis.( A) ACAT, a membrane integral enzyme is shown (yellow arrows) to convert
free cholesterol present in the endoplasmic reticulum (ER) leaflets into cholesterol esters that remain within the membrane bilayer. MTP is
shown to transfer both free cholesterol and cholesterol esters from the ER membranes to apoB-lipoproteins in the ER lumen. It should be
pointed out that MTP could transfer both free and esterified cholesterol to apoB that is still associated with membranes. The thickness of orange
arrows is meant to show that MTP most likely prefers cholesteryl esters over free cholesterol for transfer. (B) In MTP deficient conditions, transfer
of free and esterified cholesterol to apoB-lipoproteins is reduced. Initially this might lead to accumulation of cholesteryl esters. When a high
enough concentration of cholesteryl esters is achieved then ACAT activity is inhibited due to product inhibition leading to accumulation of free
cholesterol. (C) In the absence of ACAT activity, it is anticipated that cells accumulate more free cholesterol. Indeed, this is known to happen in
cells that do not secrete apoB-lipoproteins, such as macrophages. However, in cells that are able to synthesize apoB-containing lipoproteins, MTP
can transfer free cholesterol to lipoproteins avoiding excess free cholesterol accumulation in the ER membrane.
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of MTP deficiency manifests late in the life cycle of
CD1d. It is possible that CD1d molecules synthesized in
the absence of MTP have structural defects in their
hydrophobic groove as a consequence of deficient lipid
loading during biosynthesis. Therefore, they might be
unable to accept lipids in the endosomal/lysosomal
compartment resulting in the degradation of these mole-
cules rather than recycling to the cell surface with
exchanged lipids.
Besides NKT cell activation, CD1d is also critical for
the selection and development of NKT cells in thymo-
cytes [42,111]. Dougan et al. [42] studied the importance
of MTP in NKT cell development using fetal thymic
organ cultures. Treatment of these cultures with MTP
inhibitors significantly reduced the number of NKT cells
that respond to endogenous and exogenous CD1d
ligands. Thus, MTP is required for both selection and
activation of NKT cells by CD1d.
Later, Kaser et al. [122] studied the contribution of
MTP to the bioactivity of group 1 CD1 molecules.
Group 1 CD1 molecules present microbial lipopeptides,
glycolipids, fatty acids, phospholipids to diverse T cells
that express TCR-a and TCR-b chains. They showed
that MTP inhibition of monocyte derived dendritic cells
led to impaired activation of CD1a, CD1b, and CD1c
specific T cell activation. Further, presentation of both
endogenous and foreign antigens was impaired in cells
treated with MTP inhibitors. Hence, MTP also plays a
role in the presentation of endogenous and foreign anti-
gens by group 1 CD1 molecules.
As discussed before, MTP deficiency results in abetali-
poproteinemia characterized by the absence of apoB-
containing lipoproteins. Zeissig et al. [123] studied the
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Figure 2 Role of MTP in the biosynthesis of CD1 proteins: MTP transfers endogenous lipids to newly synthesized CD1 proteins in the ER (a).
CD1 proteins also associate with b2-microglobulin (b2 m) before entering the secretory pathway (b). In the absence of MTP, group 1 CD1
proteins are subjected to proteasomal degradation (c). Group 2 CD1 proteins, on the other hand, are still transported to the plasma membrane
in the absence of MTP. From the plasma membrane, CD1 proteins are constitutively internalized via clathrin-mediated endocytosis (d) and reach
endosomal recycling compartment. In this compartment, saposins remove endogenous lipids and load different lipid antigens onto CD1 proteins
(e). CD1 molecules with foreign lipids are recycled back to the plasma membrane (f), where they present their lipid antigens to restricted
population of T cells.
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CD1 molecules with dendritic cells isolated from abetali-
poproteinemia patients. They showed that monocyte
derived dendritic cells wereu n a b l et os t i m u l a t eTc e l l s
in co-cultures when incubated in the presence or
absence of exogenous antigens. Therefore, the presenta-
tion of both self and foreign antigens is defective in
monocyte-derived dendritic cells obtained from abetali-
poproteinemia patients. As discussed before, selection of
thymic iNKT cells requires CD1d and MTP. They also
measured iNKT cells and found that abetalipoproteine-
mia patients had low to undetectable levels of iNKT
cells in their plasma. These studies indicate that MTP
deficiency in humans significantly reduces CD1d
immune-mediated cytokine response by reducing the
number of iNKT cells as well as their response to cells
bearing an antigen-protein complex.
They also studied the amounts of CD1 molecules pre-
sent on the cell surface in abetalipoproteinemia dendri-
tic cells. Cell surface expression of group 1 molecules
was significantly reduced in abetalipoproteinemia
patients. Expression of group 1 CD1 molecules could be
increased when cells were incubated with proteasomal
inhibitors indicating that in the absence of MTP these
molecules undergo proteasomal degradation similar to
that shown for apoB. Despite reductions in iNKT cell
activation, cell surface expression of group 2 CD1d was
not diminished in abetalipoproteinemia monocyte-
derived dendritic cells. Further, incubation of these cells
with proteasomal inhibitors did not increase CD1d cell
surface expression. This is in contrast to observations
made in mice hepatocytes [40] suggesting for possible
cell specific differences. Therefore, it appears that bio-
synthesis and cell surface expression of group 1 CD1
proteins is more dependent on MTP than the cell sur-
face expression of CD1d.
The studies summarized above indicate that MTP is
critical for the bioactivity of CD1 molecules. To under-
stand how MTP plays a role in the biosynthesis of CD1
molecules, an in vitro assay [41] was developed based
on solid-liquid interphase apoB-MTP binding assays
[74,83,84,124] to assess whether MTP can transfer lipids
to CD1d. Purified CD1d was immobilized and incubated
with lipid vesicles that contained NBD-phosphatidy-
lethanolamine in the presence and absence of purified
MTP. MTP was able to transfer NBD-phosphatidyletha-
nolamine to CD1d but not to bovine serum albumin or
major histocompatibility complex 1 [41,42]. In contrast,
MTP was unable to transfer NBD-triacylglycerol to
CD1d. These studies indicated that MTP facilitates the
transfer of phospholipids from membranes to CD1d.
In short, it can be concluded that MTP plays a role in
the proper lipidation of CD1 proteins in the ER. After
this lipidation CD1 proteins are directed to the cell
surface and then undergo endocytosis (Figure 2). In the
endosomal/lysosomal compartment, endogenous lipids
are exchanged for a different endogenous or foreign
lipid by saposins [119,120] and recycled back to cell sur-
face. When occupied with an antigenic glycolipid or
lipopeptide, CD1 proteins interact with NKT cells (in
the case of group 2) or clonally diverse T cells (in the
case of group 1) to elicit an inflammatory response. In
the absence of MTP, group 1 CD1 molecules are per-
haps degraded by ER associated proteasomal degrada-
tion. In contrast, CD1d biosynthesis and cell surface
trafficking are less severely altered when MTP is defi-
cient. However, after internalization, its recycling to the
cell surface is impaired most likely because it is unable
to acquire lipids necessary for this event to transpire.
MTP and Hepatitis C virus
Hepatitis C virus (HCV) is the leading cause of chronic
viral hepatitis. Patients who develop the disease have an
increased risk of hepatic steatosis, cirrhosis, and hepato-
cellular carcinoma. HCV particles circulate as lipo-viral
particles which are rich in triglycerides, but also contain
apolipoprotein B, HCV RNA, and core proteins
[125-127]. The presence of HCV with apoB-lipoproteins
prompted studies to ask whether lipoprotein assembly
or MTP plays a role in viral propagation. Several studies
have now established that lipoprotein assembly and
MTP activity is required for viral production. For exam-
ple, inhibition of lipid transfer activity of MTP or siRNA
mediated knock down of apoB inhibits HCV secretion
[128-131]. But lipoprotein assembly and MTP activity is
not required for viral replication. Thus, viral replication
takes place independent of lipoprotein assembly, and
nascent viral particles get incorporated into the core of
lipoproteins prior to secretion.
Apart from the role of MTP in HCV propagation,
experiments have been performed to study the effect of
HCV on MTP. Using transgenic mice, Perlemuter et al.
[132] showed that over expression of HCV core protein
interferes with VLDL assembly and secretion. The over-
expression of viral core protein inhibited the lipid trans-
fer activity associated with MTP without affecting its
protein levels, or those of PDI, in mouse liver. This led
the investigators to conclude that HCV core protein
inhibits MTP lipid transfer activity causing hepatic stea-
tosis. Subsequent to these studies, Domitrovic et al.
[130] demonstrated that HCV non-structural proteins
decrease apoB secretion and MTP activity using a sub-
genomic replicon system in Huh-7 cells. They further
showed that reduction in MTP activity was due to a
decrease in MTP promoter activity and subsequent tran-
scription. It now appears that two mechanisms may
exist for viral-induced MTP inhibition. The first works
by decreasing transcription, while the other uses a still
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Future studies focusing on cis and trans factors respon-
sible for this response will undoubtedly further our
understanding and medical treatment of this viral
infection.
Thus, these studies indicate that although the virus
hijacks lipoprotein assembly for its secretion, high con-
centrations of virus inhibit lipoprotein assembly. There
is no good explanation to rationalize these two incom-
patible observations. It is possible that at early stages of
infection the virus hijacks lipoproteins for its propaga-
tion and transmission to other tissues [127]. However,
after reaching a higher titer, the virus might try to
undergo dormancy to avoid immune detection by slow-
ing down its propagation.
MTP as a therapeutic target
MTP has been a favorite target to lower plasma lipids
and treat disorders characterized by higher production
of apoB-containing lipoproteins such as atherosclerosis,
metabolic syndrome, familial combined hyperlipidemia,
homozygous and heterozygous familial hypercholestero-
lemia and hypertriglyceridemia [73,133-140]. Now
recognizing that MTP is also involved in the immune
response against foreign lipid antigens, targeting MTP
might also be useful for modulating the inflammatory
response during T cell mediated processes such as
inflammatory bowel disease, autoimmune hepatitis and
asthma [141]. Several MTP antagonists have been iden-
tified that decrease lipoprotein production and plasma
lipids [73,78,136,138,142]. Following promising preclini-
cal studies, some of these drugs were evaluated in
humans [140,142]. In a placebo-controlled, double-blind
dose escalation study, Implitapide (Bay-13-9952) has
been shown to reduce plasma total cholesterol, LDL
cholesterol, apoB and triglyceride with no significant
elevations in plasma transaminases [143]. A similar
study in healthy volunteers, CP-346086 significantly
reduced plasma total cholesterol, LDL cholesterol, and
apoB [138]. Cuchel et al. [144] performed dose escala-
tion studies using Lomitapide (BMS-201308 or AEGR-
733) in familial hypercholesterolemia patients with pro-
mising reductions in plasma cholesterol and apoB levels.
Samaha et al. [145] performed dose escalation studies
with Lomitapide in moderate hypercholesterolemic
patients and again found significant reductions in total
cholesterol, LDL cholesterol and apoB. These studies
provide proof of concept that MTP inhibition can be an
effective therapy to lower plasma cholesterol and apoB.
However, these studies showed that 10-30% of the indi-
viduals treated with MTP inhibitors experience
increased plasma levels of liver transaminases and
greater hepatic lipid content [144,145]. Thus, there is a
need for novel methods to inhibit MTP without
increasing hepatic lipids and plasma transaminases.
Otherwise, MTP therapy might be limited to certain
situations where alternative therapeutic interventions to
lower plasma lipids do not exist such as familial
hypercholesterolemia where the alternative treatments
(i.e. liver transplant) are associated with high risks.
To avoid hepatic lipid accumulation and plasma trans-
aminase elevation, it has been proposed that intestine-
specific MTP inhibition might be beneficial because of
t h ei n h e r e n tp r o p e r t yo ft h ei n t e s t i n et os e l f - r e n e w .I n
fact, intestine-specific MTP inhibitor, JTT-130, has been
shown to lower plasma triglyceride and LDL cholesterol
in guinea pigs without increasing hepatic triglyceride
[146]. Similarly, another intestine-specific compound,
SLx-4090, has been shown to lower plasma lipids [137].
Thus, an intestine-specific inhibition of MTP might
avoid hepatic toxicity. However, as discussed before
intestinal MTP deficiency in mice and humans is asso-
ciated with gastrointestinal disturbances such as steator-
rhea, diarrhea, flatulence, nausea, impulse to defecate,
increased stool frequency, vomiting, heartburn and sto-
mach pain. Although, these disturbances can be avoided
by administering MTP inhibitors 4 h after the meal
[142], long-term consequences related to intestine-speci-
fic MTP inhibition need careful evaluation before pro-
moting this approach.
Other strategies to garner the full potentials of MTP
therapy can also be explored. It might be possible to
capitalize on natural compounds that have been shown
to inhibit MTP activity, such as flavanoids (naringenin
from grapefruits and hesperitin from oranges) [147], iso-
flavones (genestein and daidzein from soya beans) [148]
and garlic extracts [149] for therapeutic benefits.
Another possibility is to specifically inhibit only one of
the lipid transfer activities of MTP. MTP can transfer
neutral lipids and phospholipids. Since phospholipid has
been shown to be sufficient for lipoproteins assembly
[47,70], it might be possible to inhibit its triglyceride
transfer activity to lower plasma lipids. Yet another pos-
sibility is to adapt a combined therapy involving agents
that avoid hepatic lipid accumulation along with MTP
antagonists.
Future directions
We have discussed the role of MTP in apoB-lipoprotein
assembly, cholesterol ester biosynthesis, and CD1 pro-
tein synthesis. Although significant information has
been garnered about MTP structure and activity, very
little is known about its biosynthesis and degradation.
Similarly, mechanisms controlling different levels of
M T Pe x p r e s s i o ni nd i f f e r e n ttissues and cells have not
been explained. Furthermore, the function of MTP in
different tissues and cells that do not express apoB and
CD1 proteins, such as adipocytes, needs to be
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between HCV and MTP. It is likely that MTP might
also be involved in many yet unidentified biochemical,
cellular and physiological processes.
Because of its role in apoB-lipoprotein assembly, MTP
has been targeted to reduce plasma lipids and their
atherosclerotic potential. However, these drug therapies
are associated with significant and worrisome changes in
hepatophysiology [133,144]. If safe drugs to target MTP
become available, their efficacy in the treatment of HCV
can be evaluated. Since CD1d-mediated antigen presen-
tation contributes to various immune responses asso-
ciated with infection, allergy, cancer etc., MTP
inhibitors might also be useful in reducing severity of
these responses.
Significant investments have been made in the identi-
fication and evaluation of MTP inhibitors. But, much
less time and money has been spent on explaining the
molecular basis for adverse events associated with MTP
therapy. For example, very little is known about the
types of lipids accumulating in the liver after MTP inhi-
bition and their role in the release of liver-specific trans-
aminases. Because of its role in cholesterol ester
biosynthesis, it is possible that adverse events associated
with MTP inhibition might be related to free cholesterol
accumulation. More studies are needed to establish a
cause and relationship between the types of lipids that
accumulate during MTP deficiency and their role in the
release of liver enzymes. Several approaches to avoiding
adverse events associated with MTP inhibition have
been laid out above that can be experimentally
evaluated.
An area that needs more investigation relates to
adverse events associated with intestinal MTP inhibition.
Molecular basis for diarrhea and other intestinal compli-
cations are poorly explained. Another aspect of MTP
therapy that has garnered little attention is its effect on
heart and kidney functions. Although effects on these
tissues may not be significant during acute treatments,
they could be potentially consequential in long-term
therapy.
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